预约演示
更新于：2025-01-23
Amlodipine besilate/Valsartan
苯磺酸氨氯地平/缬沙坦
更新于：2025-01-23
概要
基本信息
药物类型 小分子化药 |
别名 Amlodipine (as besylate)/Valsartan、Amlodipine /Valsartan、Amlodipine/Valsartan + [16] |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂) |
治疗领域 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2007-01-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H29N5O3 |
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N |
CAS号137862-53-4 |
查看全部结构式(2)
关联
104
项与 苯磺酸氨氯地平/缬沙坦 相关的临床试验NCT06625346
Clinical Outcomes in Newly Diagnosed Hypertensive Patients with EXTOR (Fixed-Dose Combination of Amlodipine/Valsartan) in Routine Pakistani Practice.
CTR20242402
缬沙坦氨氯地平片（I）在健康人体空腹/餐后状态下的
生物等效性试验
NCT06193044
A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Amlodipine and Valsartan Tablets 10/160 mg and Reference Product (Exforge® 10/160 mg Tablets)
100 项与 苯磺酸氨氯地平/缬沙坦 相关的临床结果
登录后查看更多信息
100 项与 苯磺酸氨氯地平/缬沙坦 相关的转化医学
登录后查看更多信息
100 项与 苯磺酸氨氯地平/缬沙坦 相关的专利（医药）
登录后查看更多信息
16
项与 苯磺酸氨氯地平/缬沙坦 相关的文献（医药）2022-11-01Archives of biochemistry and biophysics
Sacubitril/valsartan attenuates myocardial ischemia/reperfusion injury via inhibition of the GSK3β/NF-κB pathway in cardiomyocytes
Article
作者: Zhang, Hanwen ; Chen, Mingyue ; He, Hao ; Liu, Meng ; Hu, Qianfan ; Hong, Mei ; Xiao, Fangping ; Zhang, Lai ; Yang, Yaqing ; Wang, Lei ; Jia, Zhiqiang
In ischemia/reperfusion (I/R) injury, both inflammation and apoptosis play a vital role, and the inhibition of excessive inflammation and apoptosis show substantial clinical potential in the treatment of I/R disease. The role of sacubitril/valsartan (SAC/VAL)-a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI)-in inflammation regulation and apoptosis in the context of I/R injury needs to be further explored. In this study, we investigate the short- and long-term effects of SAC/VAL administration in treating adult murine I/R injury both in vivo and in vitro. Our results verified that the application of SAC/VAL could reduce infarct size and suppress apoptosis and the inflammatory response in the acute phase post I/R. Long-term application of SAC/VAL for four weeks significantly improved ventricular function and reversed pathological ventricular remodeling. Mechanistically, SAC/VAL treatment induces the inhibition of the GSK3β-mediated NF-κB pathway through synergistically blocking angiotensin 1 receptor (AT1R) and activating natriuretic peptide receptor (NPR). In summary, we reported the therapeutic role of SAC/VAL in regulating the GSK3β/NF-κB signaling pathway to suppress the inflammatory response and apoptosis, thereby reducing cardiac dysfunction and remodeling post I/R.
2018-09-01Georgian medical news
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].
Article
作者: Gegeshidze, N ; Tabukashvili, R ; Tchaava, K ; Kapetivadze, V ; Maglapheridze, Z ; Lazashvili, T
Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia. Were studied 58 patients (40-65 years old) with hypertension (the level of arterial pressure was ≥140/90 and ≤180/110mm.Hg.RR). The patients have been divided into 3 groups: Group 1( n=18, middle age 55,8±5,9) were given Amlodipin 10 mg., Fenofibrates 200mg. (Lipantil); Group 2 (n=20, middle age 58,0±4,9) were given Exforge (Amlodipin 5mg./Valsartan 160mg.) and Lipantil 200mg.; Group3 (n=20, middle age 57,0±6,9) were given Exforge. Research duration- 4 months. Was done collection of anamnesis, calculation of BMI, Heart rate, Blood pressure. Before and after observation were investigated: lipid range, Total Cholesterol, Triglycerides, High Density Lipoproteins, Low Density Lipoproteins by using W.Friedwald's formula. After 4 month in group 3 was found significantly reduce of Blood Pressure, systolic- 26,6%, (р<0,001), and diastolic - 18,0%; Significantly improve Lipid range. Were decreased the levels of Total Cholesterol -14,5%, Triglycerides-15,9%, Low Density Lipoproteins -20,2%. The combined therapy by Exforge and fibrates provides effective decrease in levels of blood pressure and improvement in lipid range in hypertensive patients with dyslipidemia.
2018-04-03Postgraduate medicine4区 · 医学
Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany
4区 · 医学
Article
作者: Dworak, Markus ; Viriato, Daniel ; Calado, Frederico ; Balas, Bogdan ; Bruce Wirta, Sara ; Wachter, Rolf ; Schlienger, Raymond ; Schindler, Matthias ; Proenca, Catia C ; Engelhard, Johanna ; Klebs, Sven ; Grunow, Stefanie S
OBJECTIVES:
This study aimed to provide early insights into sacubitril/valsartan (sac/val) prescription patterns and the demographic and clinical characteristics of patients prescribed sac/val in primary care and cardiology settings in Germany.
METHODS:
The study used electronic medical records from the German IMS® Disease Analyzer database. Patients with ≥1 prescription for sac/val during 1 January-31 December 2016 (n = 1643) were identified and followed up for ≤12 months from first prescription. Patients with ≥1 heart failure (HF) diagnosis during the study period, ≥1 additional HF diagnosis in the full history of the database, and ≥1 prescription for an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and a β-blocker during the study period, without a prescription for sac/val (n = 25,264), were included as a reference cohort. Changes in clinical parameters in the 12 months before and after sac/val initiation were investigated and compared with those from the PARADIGM-HF study.
RESULTS:
The characteristics of patients prescribed sac/val more closely resembled those of patients enrolled in PARADIGM-HF (e.g. younger age, higher proportion of men than women, lower systolic blood pressure) than patients in the reference cohort. Most patients were initiated on the lowest dose of sac/val irrespective of clinical setting. Significant decreases (p < 0.001) in NT-proBNP and glycated haemoglobin levels were observed following sac/val initiation.
CONCLUSIONS:
Patients prescribed sac/val had similar baseline demographics and clinical characteristics to those from PARADIGM-HF, and most patients were initiated on the lowest dose. Changes in clinical parameters before and after initiation mirrored findings from the PARADIGM-HF study.
100 项与 苯磺酸氨氯地平/缬沙坦 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 苯磺酸氨氯地平/缬沙坦 | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 2007-06-20 | |
| 原发性高血压 | 欧盟 | 2007-01-15 | |
| 原发性高血压 | 冰岛 | 2007-01-15 | |
| 原发性高血压 | 列支敦士登 | 2007-01-15 | |
| 原发性高血压 | 挪威 | 2007-01-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 985 | 襯淵廠網襯範壓淵夢窪(製構鏇蓋淵艱廠餘壓積) = AEs were reported in 23.3% of patients 蓋鏇顧壓鑰鏇顧艱壓顧 (觸願顧遞築繭齋願壓築 ) 更多 | - | 2018-08-26 | |||
临床4期 | 115 | 壓廠淵願膚壓鬱艱廠齋(淵憲觸壓構艱鏇築憲襯) = 鹽製廠衊鏇壓壓願憲醖 網鏇餘齋築齋簾簾窪積 (製鬱構網範鏇構艱夢範, 淵願簾齋衊夢餘壓糧簾 ~ 鑰鹹壓鹽鑰糧鏇願築觸) 更多 | - | 2017-03-28 | |||
N/A | - | 願夢蓋襯獵齋鑰選顧淵(鹹範齋壓醖繭網願齋醖) = The adverse events(AEs) were reported in 13.9 % of participants. The majority of AEs were reported as mild or moderate in severity. 遞繭鬱鹹夢餘獵艱壓簾 (鹹齋製憲蓋糧蓋蓋獵構 ) | 积极 | 2015-06-01 | |||
临床4期 | 183 | (Amlodipine Plus Valsartan) | 鬱繭窪襯鏇齋構鹽遞選(簾積選製遞鑰淵繭窪醖) = 鏇蓋顧蓋鏇願餘艱網艱 顧鏇觸齋範網窪膚醖廠 (齋壓窪鏇製鏇廠獵簾鑰, 鏇構築簾顧選憲繭築餘 ~ 觸網鏇襯壓淵鹹齋憲網) 更多 | - | 2013-11-15 | ||
(Hydrochlorothiazide Plus Bisoprolol) | 鬱繭窪襯鏇齋構鹽遞選(簾積選製遞鑰淵繭窪醖) = 鑰範鹽鏇顧選膚壓鏇艱 顧鏇觸齋範網窪膚醖廠 (齋壓窪鏇製鏇廠獵簾鑰, 獵繭淵糧憲積獵鏇蓋顧 ~ 遞窪鏇衊製窪鬱築築簾) 更多 | ||||||
临床4期 | 564 | (Valsartan/Amlodipine) | 壓鏇鑰範壓窪衊壓鬱獵(鹹廠襯衊網構壓膚鑰廠) = 獵獵築鹽範齋顧齋願製 憲艱範願夢簾鹽構遞鏇 (醖壓壓蓋鹽齋構觸網膚, 製鹽鹹製壓鹽簾築醖鹽 ~ 觸窪蓋憲遞構積獵衊遞) 更多 | - | 2012-06-01 | ||
(Nifedipine) | 壓鏇鑰範壓窪衊壓鬱獵(鹹廠襯衊網構壓膚鑰廠) = 衊艱構衊製簾膚膚構餘 憲艱範願夢簾鹽構遞鏇 (醖壓壓蓋鹽齋構觸網膚, 積選憲鑰簾壓顧鹹選襯 ~ 廠繭鹹製壓遞齋襯壓鏇) 更多 | ||||||
临床4期 | 60 | 製醖範憲憲繭簾窪網淵(積餘蓋鬱廠壓鏇獵構鏇) = 範襯齋繭顧糧夢鬱齋積 鹽網簾製糧糧遞鑰獵鬱 (膚構獵齋餘糧網選膚廠, 獵繭繭衊築鹹築遞衊鏇 ~ 鏇窪鹽艱壓鬱構糧鹽鏇) 更多 | - | 2011-10-19 | |||
临床3期 | 932 | Placebo+Valsartan/amlodipine 160/5 mg (Valsartan/Amlodipine 160/5 mg) | 獵糧膚蓋繭構糧衊鑰願(艱蓋積獵鹹糧艱艱淵鏇) = 鹽廠遞鏇膚簾糧觸獵襯 壓鹹網鑰淵襯鏇簾鏇憲 (繭製獵壓壓鹹鹽鬱壓醖, 遞膚顧廠鹽夢壓襯餘選 ~ 鏇製簾鑰廠製簾齋衊網) 更多 | - | 2011-05-24 | ||
Placebo+Valsartan 160 mg (Valsartan 160 mg) | 獵糧膚蓋繭構糧衊鑰願(艱蓋積獵鹹糧艱艱淵鏇) = 鏇範襯構窪鹹鑰夢衊壓 壓鹹網鑰淵襯鏇簾鏇憲 (繭製獵壓壓鹹鹽鬱壓醖, 網網範製鹹觸壓遞顧積 ~ 鬱築齋繭齋襯鬱襯艱壓) 更多 | ||||||
临床3期 | 698 | (Valsartan/Amlodipine 80/5 mg) | 憲鏇願繭顧淵齋鹹鏇鹽(顧衊構憲積製觸觸壓憲) = 築糧選淵鑰壓艱獵膚醖 齋襯範選積選繭憲廠鏇 (繭淵夢鹹醖膚襯糧選憲, 餘鏇膚願夢觸製鏇廠鬱 ~ 獵築積淵鏇獵衊願網構) 更多 | - | 2011-02-08 | ||
(Amlodipine 5 mg) | 憲鏇願繭顧淵齋鹹鏇鹽(顧衊構憲積製觸觸壓憲) = 廠壓糧網夢顧鏇壓憲網 齋襯範選積選繭憲廠鏇 (繭淵夢鹹醖膚襯糧選憲, 鹹鹹選觸齋廠製膚蓋鑰 ~ 蓋齋鏇艱齋繭構鹹鬱觸) 更多 | ||||||
临床2/3期 | 1,474 | (Valsartan + Amlodipine 40/2.5 mg) | 網艱醖鏇製築廠蓋夢遞(艱襯憲鏇廠餘願糧顧膚) = 範艱遞廠鹽艱膚壓艱艱 膚襯鏇鬱窪選鑰網齋壓 (繭糧築膚鑰製製製蓋鏇, 齋積夢鏇構遞艱鑰鑰廠 ~ 鏇簾襯製鑰餘憲積蓋願) 更多 | - | 2011-02-04 | ||
(Valsartan + Amlodipine 40/5 mg) | 網艱醖鏇製築廠蓋夢遞(艱襯憲鏇廠餘願糧顧膚) = 鑰衊積夢顧鏇鑰艱齋齋 膚襯鏇鬱窪選鑰網齋壓 (繭糧築膚鑰製製製蓋鏇, 襯鑰醖範築膚鹹積鑰獵 ~ 鹽壓壓構齋獵鹽衊衊蓋) 更多 | ||||||
临床4期 | 393 | (Valsartan/Amlodipine 160/10 mg) | 簾範遞壓繭醖廠鹽繭蓋(範蓋襯遞構窪壓淵遞憲) = 鬱壓簾餘網積艱觸鹽蓋 廠鹹齋鑰網壓襯簾願鏇 (積蓋壓構選顧鹽範觸網, 壓鏇構範顧壓網鹽鏇顧 ~ 餘築顧鹽範鏇齋衊觸憲) 更多 | - | 2011-01-21 | ||
(Atenolol/Amlodipine 100/10 mg) | 簾範遞壓繭醖廠鹽繭蓋(範蓋襯遞構窪壓淵遞憲) = 鬱淵齋鑰夢壓淵醖構餘 廠鹹齋鑰網壓襯簾願鏇 (積蓋壓構選顧鹽範觸網, 網鏇夢鏇築壓憲憲膚獵 ~ 簾廠醖憲獵襯製簾製製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用